JEAN EVANS: Open Payments
NPI 1649894908 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$477 in 21 payments from 12 companies in 2025. Trend: 2023 $86 · 2024 $450 · 2025 $477
Food & beverage: $477
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $142 |
| AstraZeneca Pharmaceuticals LP | 3 | $77 |
| Novo Nordisk Inc | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| SHIELD THERAPEUTICS INC | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: QULIPTA, FARXIGA, XIFAXAN, GARDASIL 9, UBRELVY, Ozempic, GEMTESA, ACCRUFER.
Industry payments across NC — which companies pay providers there.
